Open-Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis
Last updated on July 2021Recruitment
- Recruitment Status
- Enrolling by invitation
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Chronic Plaque Psoriasis
- Type
- Interventional
- Phase
- Phase 3
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 2 years and 125 years
- Gender
- Both males and females
Description
This is an open-label study in which ARQ-151 cream is applied once daily x 24 weeks to subjects with psoriasis
This is an open-label study in which ARQ-151 cream is applied once daily x 24 weeks to subjects with psoriasis
Tracking Information
- NCT #
- NCT04286607
- Collaborators
- Not Provided
- Investigators
- Study Director: David Berk, MD Arcutis Biotherapeutics, Inc.
Get Well Soon